MENU ABOUT How MannKind is changing lives for the better. More carefree moments with family and friends. More health, more happiness, more freedom. At MannKind, we don’t just want to help people manage chronic conditions–we want to help them experience the very best that life has to offer. Our team of dedicated scientists and medical professionals understands how chronic conditions can impact people’s lives because many of us live with these conditions ourselves. Through the development and commercialization of new therapeutic products and technologies, we are giving people the tools they need to truly thrive. With our ultra rapid-acting inhaled insulin, Afrezza®, we are changing the way diabetes is treated and, with our innovative and powerful Technosphere® technology, we are developing new ways for people with orphan and other serious lung diseases to take control of their health. We are driven to find new ways to change lives for the better. To keep working toward a world without limit for all. To help more people live life more humann. Our mission is to give people control of their health and the freedom to live life. Our strategy is focused on developing innovative medicines for both endocrine and orphan lung diseases. our humann values At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers we serve. do right win together own it be tenacious push boundaries A legacy of humann-focused innovation. Alfred E. Mann was a visionary in aerospace, medical technology, and biopharmaceuticals, but his true passion was helping people. During his career, he founded 17 companies and developed breakthrough medical devices, including cardiac pacemakers, insulin pumps, cochlear implants, retinal prostheses, and other technologies that enabled people to live fuller, healthier lives. In 1997, Al saw the potential of a dry powder insulin formulation to change the way diabetes is treated. He passed away in 2016, but we’re proud to have brought Afrezza® to market and continue his mission to help people not just manage their conditions, but really, truly live. our history Previous Next First international sale of Afrezza® (Brazil). 2020 2018 IND for TreT submitted to FDA; Phase 1 clinical study conducted; TreT licensed to United Therapeutics. MannKind regains commercial rights to Afrezza®, begins sales and marketing efforts. 2016 Make a humann connection with us. Reach out anytime. MannKind Corporation 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 USA contact@mannkindcorp.com 818.661.5000 sign up for email updates Terms of Use Privacy Policy Patent Notices Corporate Governance ©2021 MannKind Corporation. All rights reserved.